Nov 01, 2022 4:05pm EDT Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Company’s Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022
Oct 31, 2022 7:30am EDT Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates
Oct 04, 2022 8:00am EDT Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Sep 26, 2022 8:00am EDT Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee
Sep 21, 2022 8:00am EDT Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010
Aug 15, 2022 4:05pm EDT Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings Update
Jul 22, 2022 7:00am EDT Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy
Jul 21, 2022 7:30am EDT Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers
Jun 09, 2022 7:00am EDT Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition
